Why does capturing both poly(A) and non-poly(A) RBPs matter for target validation?

Capturing RBPs on both poly(A) and non-poly(A) RNAs expands the scope of targetable proteins beyond mRNA binders, revealing regulatory complexes involved in non-coding RNA function. This comprehensive capture reduces the risk of missing key regulators of gene expression that operate through non-coding RNA mechanisms. It supports more confident target selection by providing a complete census of RNA-interacting proteins in disease-relevant contexts.

How does metabolic labeling with EU and 4SU enable specific RNA-protein interaction capture?

Metabolic labeling incorporates bioorthogonal tags (EU and 4SU) into newly synthesized RNAs, allowing selective tagging of RNA transcripts for subsequent click chemistry conjugation. This labeling enables discrimination between newly labeled RNA and pre-existing RNA pools, reducing background in interactome capture. The dual-labeling approach supports controls to distinguish specific RNA-protein interactions from non-specific binding.

What quantitative outputs does CARIC generate for assessing RNA-binding protein enrichment?

CARIC generates biotin-tagged RNA-protein complexes that can be quantified via mass spectrometry to measure RBP enrichment across experimental conditions. The method includes quality control steps such as in-gel fluorescence and western blot to assess labeling efficiency and pulldown specificity. Silver staining of eluted proteins provides semi-quantitative assessment of total RBP capture efficiency, reported as 0.05–0.1% of input proteins in HeLa cells.

Why are replication and control conditions (no UV, no 4SU) essential for CARIC data interpretation?

Replication and control conditions (no UV, no 4SU) are critical to distinguish specific cross-linked RNA-protein interactions from non-specific background or labeling artifacts. Omitting either EU or 4SU abolishes the high-molecular-weight RNP signal, confirming dependence on both labeling and cross-linking. These controls ensure that observed RBP signals reflect bona fide in vivo interactions rather than experimental artifacts.

What statistical and analytical capabilities are required before implementing CARIC in a discovery workflow?

Implementation requires mass spectrometry platforms capable of label-free or tagged quantitative proteomics to compare RBP abundance across conditions. Bioinformatics tools are needed to process proteomic data, identify significantly enriched RBPs, and map them to RNA regulatory networks. Statistical thresholds for enrichment and reproducibility must be established to support confident target selection and mechanistic de-risking.